A Spanish research team says it has developed a treatment that completely eliminated the most aggressive form of pancreatic cancer in laboratory mice, raising fresh hopes against one of the deadliest cancers. The study, led by Mariano Barbacid at Spain’s Spanish National Cancer Research Centre, found that a newly designed triple-drug therapy wiped out pancreatic tumours with no relapse seen after treatment. After six years of work, researchers reported that the animals showed minimal side effects and no tumour recurrence, results that mark one of the most promising advances yet in pancreatic cancer research.
Pancreatic cancer and the therapy behind the breakthrough
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, is among the deadliest malignancies due to its resistance to treatment, dense tumour microenvironment, and late diagnosis. Standard therapies often fail because tumours rapidly adapt, bypassing single-target drugs.
The CNIO therapy takes a different approach. Instead of attacking one pathway, it combines three drugs to shut down multiple tumour survival mechanisms simultaneously. According to the researchers, this strategy prevents cancer cells from rewiring themselves, a common cause of treatment failure.
Barbacid has previously argued that pancreatic cancer cannot be defeated with a single-drug strategy. This tumour, he has said in earlier research discussions, is extraordinarily adaptable, and only coordinated inhibition of multiple pathways can produce lasting responses.
What the study found in laboratory models
In controlled laboratory experiments, mice with advanced pancreatic tumours experienced complete tumour elimination after receiving the triple-drug therapy. Even more notable was what happened afterwards. During extended follow-up, researchers observed no tumour regrowth, suggesting that the therapy may suppress the biological mechanisms that typically drive relapse.
The findings were published in
Proceedings of the National Academy of Sciences (PNAS), where reviewers highlighted both the durability of the response and the unusually low toxicity seen in treated animals, a critical factor for any therapy aimed at human use.
Independent cancer researchers not involved in the study have noted that durable responses without relapse are exceptionally rare in pancreatic cancer models, making the results particularly significant within the field.
Who is Mariano Barbacid?
Barbacid is one of Europe’s most influential cancer researchers. In the early 1980s, he helped identify the first human oncogene, a discovery that fundamentally reshaped modern cancer biology and established the genetic basis of cancer.
Over the past four decades, his work has repeatedly focused on KRAS-driven tumours, long considered among the hardest cancers to treat. Because KRAS mutations are present in roughly 90 per cent of pancreatic cancers, Barbacid’s sustained focus on this pathway gives the current breakthrough added weight within the scientific community.
Funding, institutions, and credibility
The research was conducted at CNIO, one of Europe’s leading cancer research institutions, with support from Fundación CRIS Contra el Cáncer, which funds high-risk, high-impact cancer research projects.
The study followed established experimental protocols and underwent independent peer review before publication. There is no evidence the findings were rushed or bypassed scientific safeguards, a point emphasised by CNIO officials amid online speculation.
Public reaction and online controversy
News of the breakthrough spread rapidly across social media, generating both excitement and scepticism. Many users hailed the findings as a cure, while others questioned whether pharmaceutical or regulatory barriers could delay progress.
Such reactions reflect a broader tension in cancer research communication, namely the gap between legitimate scientific caution and public desperation for definitive cures, particularly for diseases with historically grim outcomes.
What happens next
The next phase involves further validation studies and safety testing, followed, if funding and regulatory approvals allow, by early-stage human trials. While a confirmed cure for pancreatic cancer in people remains years away, experts agree that this research provides one of the strongest indications yet that the disease may finally be vulnerable to targeted combination therapies rather than incremental treatment gains.